Abstract WMP57: Acute Stroke Interventions And Clinical Outcomes In Patients With Solid Organ Malignancies

Abstract

Background: There is limited data regarding the safety of acute ischemic stroke (AIS) treatments in patients with solid organ malignancy (SOM). We aimed to evaluate the nationwide use of acute stroke interventions and clinical outcomes in this patient population. Methods: Adult hospitalizations with primary diagnosis of AIS were identified from the Nationwide Readmissions Database 2016-2018. Logistic regression was used to compare the differences in interventions and clinical outcomes in patients with and without SOM. Survival analysis was used to evaluate recurrent AIS after discharge. Results: There were 1385840 hospitalizations due to AIS (mean±SD age 70.4±14.0 years, female 50.2%). Of these, 50553 (3.7%) had a concurrent diagnosis of SOM. Patients with SOM were older, more likely to be male, and had a lower prevalence of comorbid cerebrovascular risk factors, except atrial fibrillation and tobacco use. The five most common malignancies were of lung, prostate, breast, pancreas, and colorectal origins. After adjustment for baseline differences, patients with SOM were more likely to have intraparenchymal hemorrhage (IPH) [odds ratio (OR): 1.1, 95% confidence interval (CI): 1.0-1.2], in-hospital mortality (OR: 2.1, 95% CI: 2.0-2.2), and discharge disposition other than to home (OR: 1.6, 95% CI: 1.6-1.7). The risk of IPH was higher only in pancreatic cancer, in-hospital mortality in all types except prostate cancer, and adverse discharge disposition in all types except prostate and breast cancers. Patients with SOM were less likely to receive intravenous thrombolysis (tPA) but more likely to undergo endovascular thrombectomy (ET). Among the subgroups of patients treated with tPA or ET, outcomes were comparable between patients with and without SOM, except patients with lung cancer remained at a higher risk of mortality and adverse disposition despite these interventions. Patients with SOM had higher risk of readmission due to recurrent AIS within 1 year of discharge (hazards ratio: 1.2, 95% CI: 1.1-1.3), and this risk was entirely driven by lung and pancreatic cancers. Conclusion: Clinical outcomes of AIS in the setting of SOM vary according to the malignancy site. Acute stroke interventions when performed, appear to be safe in most patients with SOM.